Lytgobi

Active Ingredient(s): Futibatinib
FDA Approved: * September 30, 2022
Pharm Company: * TAIHO ONCOLOGY
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Lytgobi 4 mg Oral Tablet
NDC: 64842-0120
Labeler:
Taiho Pharmaceutical Co., Ltd.